21:38 , Dec 1, 2017 |  BC Week In Review  |  Clinical News

Arbutus' ARB-1467 leads to HBsAg responses in Phase IIa for HBV infection

Arbutus Biopharma Corp. (NASDAQ:ABUS) reported data from 11 evaluable hepatitis B e antigen (HBeAg)-negative patients with chronic HBV infection in cohort 4 of the Phase IIa ARB-1467-002 trial showing that 0.4 mg/kg IV ARB-1467 every...
22:21 , Oct 12, 2017 |  BC Innovations  |  Targets & Mechanisms

Mining the negatives

By investigating why its discontinued siRNA candidate against hepatitis B caused only weak responses in certain patients, Arrowhead Pharmaceuticals Inc. has upended a dogma about the virus’ genetics that has been clouding drug design and...
00:42 , Aug 12, 2017 |  BioCentury  |  Product Development

HBV test kitchen

Early results for HBV monotherapies are pointing the way toward combinations that could deliver a functional cure. What remains unknown is how many components, and which ones, will prove necessary to eliminate remnants of the...
07:00 , May 23, 2016 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changesCompanyBankAnalystCoverageOpinionWk chg5/20 clsArbutus Biopharma Corp. (NASDAQ:ABUS)Chardan CapitalMadhu KumarNewSell-6%$4.08 Kumar initiated coverage with a $3.25 target, saying competition to Arbutus' lead asset, ARB-1467, raises hurdles ahead of 2H16 catalysts. He...
07:00 , Oct 12, 2015 |  BC Week In Review  |  Clinical News

Arbutus Biopharma preclinical data

In a mouse model of HBV infection, 4 weekly doses of 0.3 mg/kg TKM-HBV reduced HBV covalently closed circular DNA levels by 42% vs. untreated control animals. This quarter, Arbutus expects data from a Phase...
00:46 , Jul 21, 2015 |  BC Extra  |  Company News

Tekmira changing name to Arbutus with HBV focus

Tekmira Pharmaceuticals Corp. (NASDAQ:TKMR) said it will change its name to Arbutus Biopharma Corp., effective Aug. 3, and will focus on developing HBV therapies. It will form a separate business unit for non-HBV therapies, and...
08:00 , Feb 2, 2015 |  BC Week In Review  |  Clinical News

TKM-HBV: Phase I started

Tekmira began a single-blind, placebo-controlled, Canadian Phase I trial to evaluate single ascending doses of 2 formulations of IV TKM-HBV in about 40 healthy volunteers. Tekmira Pharmaceuticals Corp. (TSX:TKM; NASDAQ:TKMR), Burnaby, B.C.   Product: TKM-HBV...
08:00 , Jan 19, 2015 |  BC Week In Review  |  Company News

OnCore Biopharma, Tekmira deal

OnCore will merge with a wholly owned subsidiary of Tekmira in a deal that the companies say value the the combined companies at about $750 million, based on Tekmira’s close of $15.70 on Jan. 9,...
08:00 , Jan 19, 2015 |  BioCentury  |  Finance

Valuing OnCore

At roughly half a billion dollars, OnCore Biopharma Inc.'s value point in its planned merger with RNAi play Tekmira Pharmaceuticals Corp. (TSX:TKM; NASDAQ:TKMR) is likely far above what the preclinical infectious disease company would have...
08:00 , Jan 19, 2015 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changesCompanyBankAnalystCoverageOpinionWk chg1/16 clsDepomed Inc. (NASDAQ:DEPO)Roth Capital PartnersScott HenryUpgradeBuy (from neutral)17%$20.20 Henry also raised his target to $25 from $13.50 after Depomed acquired U.S. rights to the Nucynta tapentadol analgesic...